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Identifying patients at risk of exacerbations and managing them appropriately to reduce this risk represents an
important clinical challenge. Numerous treatments have been assessed for the prevention of exacerbations and
their efficacy may differ by patient phenotype. Given their centrality in the treatment of COPD, there is strong
rationale for maximizing bronchodilation as an initial strategy to reduce exacerbation risk irrespective of patient
phenotype. Therefore, in patients assessed as frequent exacerbators (>1 exacerbation/year) we propose initial
bronchodilator treatment with a long-acting muscarinic antagonist (LAMA)/ long-acting β2-agonist (LABA). For
those patients who continue to experience >1 exacerbation/year despite maximal bronchodilation, we advocate
treating according to patient phenotype. Based on currently available data on adding inhaled corticosteroids (ICS)
to a LABA, ICS might be added to a LABA/LAMA combination in exacerbating patients who have an asthma-COPD
overlap syndrome or high blood eosinophil counts, while in exacerbators with chronic bronchitis, consideration
should be given to treating with a phosphodiesterase (PDE)-4 inhibitor (roflumilast) or high-dose mucolytic agents.
For those patients who experience frequent bacterial exacerbations and/or bronchiectasis, addition of mucolytic
agents or a macrolide antibiotic (e.g. azithromycin) should be considered. In all patients at risk of exacerbations,
pulmonary rehabilitation should be included as part of a comprehensive management plan.
Keywords: Emphysema, Bronchitis, Exacerbation, Risk factors, Guidelines, Prevention, Treatment, Phenotypes
Abbreviations: ACOS, Asthma-COPD overlap syndrome; ATS, American Thoracic Society; COPD, Chronic obstructive
pulmonary disease; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints;
ERS, European Respiratory Society; FEV1, Forced expiratory volume in 1 second; GOLD, Global initiative chronic
Obstructive Lung Disease; ICS, Inhaled corticosteroid; LABA, Long-acting β2 agonist; LAMA, Long-acting muscarinic
antagonist; PDE, Phosophodiesterase; REACT, Roflumilast and Exacerbations in patients receiving Appropriate
Combination Therapy; UPLIFT, Understanding Potential Long-term Impacts on Function with TiotropiumBackground
The consequences of a chronic obstructive pulmonary
disease (COPD) exacerbation are many. Adverse effects
of an exacerbation include a negative impact on patient
quality of life [1, 2], an effect on symptoms and lung
function that are associated with a lengthy recovery [3],
an accelerated rate of decline in lung function [4, 5] and
hospital admissions [6]. Moreover, exacerbations may
result in significant mortality, particularly in cases that* Correspondence: mmiravitlles@vhebron.net
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high socioeconomic burden, with exacerbations ac-
counting for most of total COPD healthcare expend-
iture [8]. Therefore, any COPD exacerbation should not
be underestimated given their detrimental impact, and
their prevention is a key goal of COPD treatment [9]. It
is useful to consider that exacerbations are heteroge-
neous events and the nature of exacerbations is likely
to differ between different subgroups of patients with
COPD, such as patients with chronic bronchitis or se-
vere emphysema [10].le is distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Risk factors for exacerbations of chronic obstructive
pulmonary disease [6, 21–23, 25, 122]
Risk factors
• Older age
• Lower body mass index
• Continued smoking
• Poor exercise capacity
• Severity of airflow obstruction
• Previous exacerbations (including hospitalizations for exacerbations)
• Longer duration of chronic obstructive pulmonary disease
• Co-morbidities (e.g. bronchiectasis, cardiovascular disease, pulmonary
hypertension, gastroesophageal reflux)
• Respiratory tract infections (viral and bacterial
• Chronic bronchial mucus production
• Environmental pollutants
• Colder weather/temperature
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aging patients with COPD according to their risk and
type of exacerbation and discusses current and evolving
preventative strategies. Selection of the studies included
in the ‘Pharmacologic therapies to prevent COPD exac-
erbations’ section of this paper were identified via a
PubMed search [details provided in Additional file 1].
Given the nature of this review, the studies referred to
herein did not need to adhere to any pre-specified ex-
acerbation definition.
Identifying patients at risk of COPD exacerbations
How do we define an exacerbation of COPD?
Although most guidelines define exacerbations similarly,
there are differences in the exact definition used [see
Additional file 1: Table S1, which provides a non-
comprehensive list of exacerbation definitions used
within a selection of societal guideline documents]. Varia-
tions in the definition of exacerbations within clinical
studies also exist [11]. Clinical trials use event-based defi-
nitions of exacerbation, which necessitate an increase in
symptoms and the use of healthcare resources [12, 13],
and grade exacerbations based on their severity, e.g. mod-
erate exacerbations as those requiring treatment with sys-
temic corticosteroids/antibiotics and severe exacerbations
as those necessitating hospitalization [14–16]. In an at-
tempt to establish a uniform definition of exacerbations to
be used as an outcome measure in clinical trials, the
European Respiratory Society (ERS) and the American
Thoracic Society (ATS) task force defined an exacerbation
as an increase in respiratory symptoms over baseline that
usually requires a change in therapy [17]. It is relevant to
note that many exacerbations go unreported and un-
treated [18, 19].
Key risk factors for COPD exacerbation
Numerous factors may contribute to a COPD exacerba-
tion, the most frequent cause of which is a respiratory
tract infection [20–22]. However, other factors also play
a contributing role, as shown in Table 1, including a
change in weather/temperature [23], air pollution [24],
and comorbid conditions [6, 25].
Some patients may be more susceptible to developing
COPD exacerbations than others, and are generally re-
ferred to as ‘frequent exacerbators’. In the Evaluation of
COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) study, an analysis of exacerbations in
2138 patients demonstrated that the single best predictor
of frequent exacerbations was an exacerbation in the pre-
ceding year [14]. In addition, exacerbations were more fre-
quent and more severe (associated with hospitalization) in
patients with advanced airflow obstruction [14]: 22 % of pa-
tients with Global initiative for chronic Obstructive Lung
Disease (GOLD) 2 disease, 33 % with GOLD 3 and 47 %with GOLD 4 disease had frequent exacerbations (≥2) in
the first year of follow-up. Other factors associated with in-
creased exacerbation frequency were increased rate of lung
function decline (100 mL decrease in forced expiratory vol-
ume in 1 s (FEV1) and a history of reflux or heartburn [14].
In addition, a low level of physical activity can also predict
future exacerbations [26, 27], independent of pulmonary
function and previous exacerbation history [27].
Several studies have demonstrated that a chronic bron-
chitis phenotype is associated with an increased risk of ex-
acerbations in patients with COPD [28–30]. However,
patients with an emphysematous phenotype are also likely
to exacerbate more frequently, in particular if they have
severe emphysema [31].
Assessment of exacerbation risk: what do guidelines say?
COPD guidelines have historically just used lung func-
tion to grade the severity of disease, and guide treatment
strategies. A more complex approach has been adopted
recently, incorporating other clinical features to define
clinical phenotypes. A phenotype is defined as “a single
or combination of disease attributes that describe differ-
ences between individuals with COPD as they relate to
clinically meaningful outcomes (symptoms, exacerba-
tions, response to therapy, rate of disease progression, or
death)” [32]. The aim of phenotyping is to enable identi-
fication of patient groups that have distinctive prognos-
tic or therapeutic characteristics, thereby enabling a
personalized approach to treatment.
The definition of the “frequent exacerbator” phenotype,
based on findings from the ECLIPSE study [14], has been
incorporated into many COPD guidelines. Current GOLD
strategy advocates assessment of exacerbation risk by: (i)
GOLD spirometric classification, with GOLD 3 and 4 indi-
cating high risk; or (ii) a history of exacerbations, with ≥2
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in the previous year indicating high risk [9]. GOLD
subdivides patients into four categories, A, B, C or D, on
the basis of symptoms and risk, with the aim of using this
clinical assessment to make treatment decisions. Guidelines
differ in how the risk of future exacerbations is assessed (see
Additional file 1: Table S2), with a previous history of exac-
erbations being a common feature of many [9, 33–38], but
other characteristics such as FEV1 included in some [9, 34,
35, 37], but not all, guidelines, e.g. Spanish GesEPOC and
the Saudi Thoracic Society [33, 36, 38]. In fact, the Spanish
(GesEPOC) guidelines have adopted a different approach to
other national guidelines. Four clinical phenotypes are de-
fined [33]: non-exacerbators (<2 exacerbations/year), an
asthma-COPD overlap syndrome phenotype (ACOS), and
two groups of frequent exacerbators (≥2 exacerbations/
year), specifically exacerbators with emphysema and exacer-
bators with chronic bronchitis. Importantly, patients with
ACOS experience more frequent and severe exacerbations,
as well as worse disease-related quality of life, compared
with patients having COPD [33, 39–41].
The main problem associated with the implementation
of the GOLD strategy comes from the inclusion of pa-
tients with either poor lung function or exacerbations or
both into the same categories C or D. An analysis of sev-
eral large study databases has reported that, of those pa-
tients categorized as GOLD D (i.e. at high risk), most
(63–79 %) qualify based solely on airflow limitation
(FEV1 < 50 % predicted) and not prior exacerbation fre-
quency [42]. This heterogeneity of patients qualifying by
different criteria (airflow restriction or exacerbation fre-
quency, or both) for GOLD groups C and D [9] can
prove a challenge for physicians wishing to individualize
treatment, as patients in these categories may have dif-
ferent levels of exacerbation risk and may require differ-
ent treatment approaches. For example, the COPDGene
study showed significant (p < 0.0001) differences in ex-
acerbation rates depending on whether patients were
categorized as GOLD D based on lung function alone
(0.89 exacerbations/person-year), on previous exacerba-
tion history only (1.34 exacerbations/person-year) or
both criteria (1.86 exacerbations/person-year) [43].
Phenotypes of COPD exacerbations
Bafadhel et al have demonstrated that phenotypes of exac-
erbations exist comprising four biologic exacerbation clus-
ters: bacterial, viral, eosinophilic and pauci-inflammatory
[10]. The type of inflammatory response during an exacer-
bation (eosinophilic vs neutrophilic) may depend on the
patient phenotype in stable state [44–46]. Individuals with
eosinophilic exacerbations tend to have increased levels of
sputum eosinophils in a stable condition, suggesting that
patient phenotypes in stable COPD and exacerbations of
COPD are closely related [10, 46]. Eosinophilic airwayinflammation occurs in exacerbations of both COPD and
asthma [47], and it has previously been shown that periph-
eral and sputum eosinophil counts are higher in patients
with concomitant COPD and asthma, i.e. ACOS compared
with COPD alone [48, 49]. Montuschi et al describe the
possibility of an association between (1) infective exacerba-
tions and a chronic bronchitis phenotype; (2) pauci-
inflammatory exacerbations with an emphysema pheno-
type; and (3) eosinophilic exacerbations with an ACOS
phenotype [50]. We agree with the authors that confirma-
tory studies are required in this regard, particularly in light
of data showing increased sputum neutrophil counts in in-
dividuals with ACOS [51]. At present, therefore, sputum
eosinophilia or neutrophilia cannot be used as a distin-
guishing feature for ACOS [52].
Phenotypes of COPD exacerbations is an interesting
area of discussion and deserves greater focus than can
be given in the current paper. Nevertheless, in addition
to demonstrating specific biologic exacerbation clusters,
Bafadhel et al identified specific biomarkers for clinical
phenotypes during exacerbations, i.e. those associated
with bacteria (sputum IL-1β), virus (serum CXCL10)
and sputum eosinophilia (peripheral eosinophils), which
may help direct pharmacological treatment [10].
Non-pharmacologic therapy to prevent COPD
exacerbations
A number of non-pharmacologic strategies exist to pre-
vent COPD exacerbations including smoking cessation,
which is perhaps one of the most efficacious interven-
tions in individuals who continue to smoke [53], vaccin-
ation, pulmonary rehabilitation and disease management
programs/patient education [6].
Pulmonary rehabilitation, defined by the ATS/ERS as a
comprehensive intervention that includes thorough patient
assessment followed by patient-tailored therapies such as
exercise training, education and behaviour change [54], also
has convincing evidence of its efficacy in improving quality
of life, exercise capacity ond reducing the readmission rates
during the period following an exacerbation, although its
effect on reducing exacerbation rates are limited [6]. In a
meta-analysis of nine trials involving 432 patients with
COPD, pulmonary rehabilitation was associated with sig-
nificant reductions compared with conventional commu-
nity care in relation to hospital admissions (odds ratio [OR]
0.22, 95 % CI 0.08, 0.58) and mortality (OR 0.28, 95 % CI
0.10, 0.84), with improvements also observed for health-
related quality of life (QoL) and exercise capacity [55].
Pharmacologic therapies to prevent COPD exacerbations
Characterizing COPD phenotypes [56] may identify patients
who will respond better to a specific type of treatment and
thereby individualize therapy [57, 58]. Unfortunately, clinical
trial inclusion criteria do not always match the phenotypes
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frequency may not be specified as an inclusion criterion, or
if exacerbation criteria are specified, the frequency (≥1) may
be different than those specified by guidelines (≥2). The fol-
lowing pharmacologic therapies employed in the manage-
ment of COPD are reviewed with a specific focus on their
effect on the risk of exacerbations (Tables 2, 3 and 4), and
evidence for use in specific COPD phenotypes.
Long-acting bronchodilators
Bronchodilation with long-acting muscarinic antagonists
(LAMAs) and long-acting β2-agonists (LABAs), alone or
in combination, is a recommended treatment option for
most patients with COPD [9, 34, 35, 59]. Long-acting
bronchodilators reduce exacerbation risk by improving
expiratory airflow when patients are stable, thereby de-
creasing air trapping that develops during an exacerba-
tion [11].
Several studies have demonstrated the efficacy of long-
acting bronchodilators in reducing exacerbation risk in
populations of patients with or without a history of exac-
erbations (Table 2). Some of these studies have specific-
ally recruited patients with a history of ≥1 exacerbation
in the previous year, in order to “enrich” the population
with patients more likely to exacerbate during the study
period [60–64]. Table 2 shows that long-acting broncho-
dilators reduce exacerbation rates compared with pla-
cebo both in these “enriched” populations and in studies
where there were no specific inclusion criteria regarding
exacerbation history. This demonstrates the broad ability
of long-acting bronchodilators to prevent future exacer-
bations irrespective of previous exacerbation history.
LABA monotherapy with salmeterol has been shown
to reduce the annual rate of moderate or severe exacer-
bations by 15 % compared with placebo (p < 0.001) in a
population of patients that may or may not have a his-
tory of exacerbations [13] and by 20 % compared with
placebo (p = 0.003) in patients with more than one ex-
acerbation in the prior year [65] (Table 2). Other LABAs
seem to be effective at reducing exacerbations, and in a
post-hoc pooled analysis of 6-month data from three
large Phase III trials of indacaterol 150 and 300 μg once
daily versus placebo in 2716 patients with moderate-
to-severe COPD, exacerbation rates were significantly
reduced by about 30 % with both doses of indacaterol
(rate ratios: 0.69; 95 % confidence interval [CI] 0.55,
0.87 and 0.71; 95 % CI 0.57, 0.88, respectively; both
p = 0.002) [66].
The Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) trial in patients
with stable COPD demonstrated a 14 % reduction in ex-
acerbations with tiotropium 18 μg once daily versus
usual treatment at 4 years’ follow-up (p < 0.001) [15]. In
a recent systematic review of 22 studies and >23,000patients with stable COPD, which included UPLIFT, tio-
tropium was associated with a 22 % reduction in exacerba-
tions versus placebo (OR 0.78; 95 % CI 0.70, 0.87) [67].
Other LAMAs have also demonstrated efficacy on exacer-
bations. In the GLOW 1 and 2 studies, where ~95 % of
patients had an exacerbation history of 0 or 1 at baseline,
glycopyrronium significantly reduced the risk of first mod-
erate or severe exacerbation (by 31 %, p < 0.05) and the
rate of moderate or severe COPD exacerbations (by 34 %,
p = 0.001) versus placebo [68, 69]. Data on exacerbations
with aclidinium are mixed, with one study showing fewer
patients experiencing a moderate or severe exacerbation
(hazard ratio [HR] 0.7; 95 % CI 0.55, 0.90; p = 0.0046)
compared with placebo, and another study showing no ef-
fect [70], although the overall exacerbation rate was low,
which can reduce the ability to detect an effect of treat-
ment. Studies specifically in patients with prior exacerba-
tions suggest that LAMAs may be more effective than
LABAs at reducing the risk of exacerbations [60, 63]. For
example, in the Prevention Of Exacerbations with Tiotro-
pium in COPD (POET-COPD) study, which included pa-
tients having had at least one exacerbation requiring
treatment or hospitalization in the previous year, tiotro-
pium significantly reduced the risk of exacerbations by
17 % versus salmeterol (p < 0.001) [60]. Genotyping of a
subgroup of patients in this study highlighted that poly-
morphisms of the β2-adrenoceptor can affect exacerbation
outcomes in response to salmeterol but not tiotropium
[71], and this may have contributed to the difference be-
tween treatments in exacerbations.
Data are emerging on the benefits of LABA/LAMA
combination therapies in reducing the risk of exacerba-
tions versus various comparators. In a pooled analysis of
two 6-month randomized trials, aclidinium/formoterol
(LABA/LAMA fixed combination) reduced the rate of
moderate or severe exacerbations by 29 % compared
with placebo (p < 0.05) [72]. In the SPARK study of 2224
patients with GOLD stages 3–4 COPD and ≥1 moderate
COPD exacerbation in the past year, indacaterol/glyco-
pyrronium (IND/GLY) significantly reduced the rate of
moderate-to-severe exacerbations by 12 % (p = 0.038)
and all exacerbations by 15 % (p = 0.0012) compared
with glycopyrronium monotherapy. In addition, IND/
GLY reduced the risk of all exacerbations vs tiotropium
monotherapy (14 %; p = 0.0017) and had a trend to a re-
duction in the risk of moderate-to-severe exacerbations
(10 %; p = 0.096) [62]. Recently, the LANTERN study of
744 patients with moderate-to-severe COPD and one or
no exacerbations in the previous year reported a signifi-
cant 31 % reduction in the rate of moderate or severe
exacerbations (an exploratory endpoint) with IND/GLY
compared with salmeterol/fluticasone propionate (SFC)
(p < 0.05) [73]. The FLAME study has investigated the
effect of IND/GLY compared with SFC on exacerbations










Exacerbation entry criteria (No./year) FEV1 % predicted
LAMA
Glycopyrronium [69] 0.54 Placebo 0.80 34 % Secondary (moderate
or severe)
NA ≥30– < 80 % (post-BD)
Glycopyrronium [68] 0.43 Placebo 0.59 NS Secondary (moderate
or severe)
NA ≥30– < 80 % (post-BD)
Tiotropium [63] 0.61 Indacaterol 0.79 29 % Secondary (all) ≥1 ≥30– < 50 % (post-BD)
Tiotropium [60] 0.64 Salmeterol 0.72 11 % Primary (moderate
or severe)
≥1 <70 % (post-BD)
Tiotropium [123] 0.69 Placebo 0.87 21 % Secondary (any) NS ≤60 % (pre-BD)
Tiotropium [15] 0.73 Placebo 0.85 14 % Secondary (moderate) NA <70 % (post-BD)
Tiotropium [124] 1.17 Placebo 2.46 52 % Secondary (any) NA <80 %
Tiotropium [125] 1.57 Placebo 2.41 35 % Secondary (any) ≥1 30–65 % (pre-BD)
Tiotropium [126] 0.85 Placebo 1.05 20 % Secondary (any) NA ≤60 %






Secondary (any) NA ≤65 %
Tiotropium [128] 0.73 Placebo 0.96 24 % Secondary (any) NA ≤65 %
Tiotropium [129] 0.76 Placebo 0.95 20 % Secondary (any) NA ≤65 %
LABA
Salmeterol [13] 0.97 Placebo 1.13 15 % Secondary (moderate
or severe)
NA <60 % (pre-BD)
Salmeterol [65] 1.04 Placebo 1.30 20 % Secondary (any) ≥1 25–70 % (pre-BD)
LAMA/LABA
Acl/Form [72] 0.42 Placebo 0.29 29 % (pooled data) Moderate or severe NA ≥30– < 80 % (post-BD)
IND/GLY [62] 0.84 Glycopyrronium 0.95 12 % Primary (moderate
or severe)
≥1 <50 % (post-BD)
Tiotropium + salmeterol [64] 1.75 Tiotropium 1.61 NS Secondary (any) ≥1 <65 % (post-BD)
UMEC/VIL [130] NR Tiotropium NR NS Secondary endpoint NA ≤70 % (post-BD)
Studies identified using PubMed search of key terms and limited to clinical trials published in English language and including at least 100 patients. Results were manually filtered for relevance and additional studies
added at the author’s discretion. Reductions in exacerbations vs comparator were statistically significant unless otherwise stated (See Additional file 1 for detailed description of term used in searchs)
Acl aclidinium, BD bronchodilator, Form formoterol, GLY glycopyrronium, IND indacaterol, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, NA not applicable, NR not reported, NS not significant,











Table 3 Effect of ICS based therapies on the risk of COPD exacerbation











FP [131] 0.93 Placebo 0.73 NS Primary NA <90 % (post-BD)
FP [13] 0.93 Placebo 1.13 18 % Secondary (moderate or severe) NA <60 % (pre-BD)
FP [65] 1.05 Placebo 1.30 19 % Secondary (any) ≥1 25–70 % (pre-BD)
FP [132] 0.99 Placebo 1.32 25 % Secondary (any) NA <85 % (post-BD)
LABA/ICS
SFC [133] 0.44 Salmeterol 0.48 NS Primary (severe) ≥1 (last 14 days) <70 % (pre-BD)
SFC [134] 1.10 Salmeterol 1.59 30.4 % Primary (moderate or severe) ≥1 <50 %









Secondary (moderate or severe) NA <60 % (pre-BD)
SFC [65] 0.97 Placebo 1.30 25 % Secondary (moderate) ≥1 25–70 % (pre-BD)
SFC [135] 1.06 Salmeterol 1.53 30.5 % Primary ≥1 <50 %
SFC [61, 136] 1.28 Tiotropium 1.32 NS Primary (moderate or severe) NA <50 % (post-BD)
SFC [137] 0.92 Salmeterol 1.4 35 % Primary (moderate or severe) ≥2 <50 % (post-BD)









Primary (all) ≥1 <50 % (pre-BD)









Primary (severe) ≥1 <50 %
Bud/Form [138] 0.70 (320/9 μg)
0.79 (160/9 μg)
Formoterol 1.07 34.6 %
25.9 %
Primary (moderate or severe) ≥1 ≤50 % (pre-BD)
Bud/Form [139] NR Formoterol NR 36 % Secondary (any) ≥1 ≤50 % (pre-BD)
FF/VI [79] 0.81 Vilanterol 1.11 30 %(Pooled data) Primary (moderate or severe) ≥1 <70 % (post-BD)
BDP/FOR [140] 0.80 Formoterol 1.12 28 % Primary (moderate or severe) ≥1 <50 %




NS Primary ≥1 30–50 % (post-BD)
Triple therapy
Tiotropium + salmeterol + FP [64] 1.37 Tiotropium 1.61 NS Secondary (any) ≥1 <65 % (post-BD)
Studies identified using PubMed search of key terms and limited to clinical trials published in English language and including at least 100 patients. Results were manually filtered for relevance and additional studies
added at the author’s discretion. Reductions in exacerbations vs comparator were statistically significant unless otherwise stated (See Additional file 1 for detailed description of term used in searchs)
BD bronchodilator, BDP/FOR beclomethasone dipropionate/formoterol fumarate, FP fluticasone propionate, ICS inhaled corticosteroid, IND/GLY indacaterol/glycopyrronium, LABA long-acting β2-agonist, SFC salmeterol/











Table 4 Effect of other therapies on the risk of COPD exacerbation











Azithromycin [107] 1.94 Placebo 3.22 42 % Primary (any) ≥3 NA
Azithromycin [108] 1.48 Placebo 1.83 27 % Primary (moderate or severe) ≥1 severe <70 % (post-BD)
Azithromycin [142] 2.8 Baseline 6.8 59 % Moderate or severe ≥4 <50 % (post-BD)
Erythromycin [143] 1 Placebo 2 35 % Primary (moderate or severe) NA 30–70 %
Mucolytics
Carbocysteine [144] 1.01 Placebo 1.35 25 % Primary (any) ≥2 in 2 years 25–79 %
N-acetylcysteine (high dose) [113] 1.16 Placebo 1.49 22 % Primary (any) NA 30–70 %
N-acetylcysteine [114] 0.96 Placebo 1.71 43.9 % Secondary ≥1 Not stated
N-acetylcysteine [131] 1.00 Placebo 0.73 NS Primary NA <90 % (post-BD)
N-acetylcysteine [145, 146] 1.25 Placebo 1.29 NS Primary ≥2 (previous 2 years) 40–70 % (post-BD)
PDE-4 inhibitor
Roflumilast [99] 0.81 Placebo 0.93 NS Primary (moderate or severe) ≥2 (and chronic cough/sputum) <50 % (post-BD)
Roflumilast [147] 1.14 Placebo 1.37 16.9 % Primary (moderate or severe) ≥1 ≤50 % (post-BD)
Roflumilast [97] 1.14 Placebo 1.37 17 % (2 studies
pooled)
Primary (moderate or severe) ≥1 (and chronic cough/sputum) <50 % (post-BD)
Roflumilast [148] 0.86 Placebo 0.92 NS Primary (moderate or severe) NA <50 % (post-BD)
Studies identified using PubMed search of key terms and limited to clinical trials published in English language and including at least 100 patients. Results were manually filtered for relevance and additional studies
added at the author’s discretion. Reductions in exacerbations vs comparator were statistically significant unless otherwise stated (See Additional file 1 for detailed description of term used in searchs)
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with a history of exacerbations [74], and demonstrated
that IND/GLY was more effective than SFC for reducing
the rate of all exacerbations by 11 % (p = 0.0003) and
moderate or severe exacerbations by 17 % (p < 0.001)
[74]. Moreover, although the annual rate of severe exac-
erbations did not reach statistical significance between
the two treatment arms due to the low number of
events, the time to first severe exacerbation was signifi-
cantly longer with IND/GLY compared with SFC (19 %
lower risk, p = 0.046).
Much data are available demonstrating the effectiveness
of long-acting bronchodilators in terms of exacerbation
reduction in patients with COPD, with studies showing
rate reductions compared with placebo of up to 20–30 %
with LABAs and 34–35 % with LAMAs (Table 2). Inter-
estingly, combining a LABA and LAMA results in a re-
duction of risk compared with a LAMA alone and, more
importantly, a significant reduction of exacerbation risk
compared with a LABA/ICS [62, 73, 74].
Inhaled corticosteroids and long-acting bronchodilators
Inhaled corticosteroids (ICS) are generally licensed in
COPD for use in combination with a LABA for patients
with a history of exacerbations in the past year [9].
GOLD recommends that patients with ≥2 exacerbations
(or one hospitalization) should be considered for ICS/
LABA treatment [9], and this is also echoed in other
guidelines [34–37]. The Spanish, the Finnish and Czech
guidelines recommend ICS for patients classified as fre-
quent exacerbators or of the ACOS phenotype [33–35].
Although ICS alone have been shown to produce mod-
est reductions in the occurrence of exacerbations [75],
their efficacy is enhanced when combined with a LABA,
as demonstrated in a Cochrane review and in a Bayesian
network meta-analysis [76, 77]. In the Towards a Revolu-
tion in COPD Health (TORCH) study1, SFC was associ-
ated with a 25 % reduction in exacerbation rate versus
placebo (p < 0.001), a 12 % reduction versus salme-
terol (p = 0.002) and a 9 % reduction versus fluticasone
propionate (p = 0.02) [13] (Table 3). Although SFC was
more effective than salmeterol monotherapy for reducing
the risk of moderate-to-severe exacerbations, there was no
significant difference in the risk of severe exacerbations (re-
quiring hospitalization) [13]. Similarly, in a study2 of 797
patients with COPD (FEV1 < 50 % predicted and at least
one exacerbation in the year prior to the study), SFC sig-
nificantly reduced the annual rate of moderate/severe exac-
erbations (30.4 %, p < 0.001) versus salmeterol [78]. An
analysis of pooled data from two studies2 in which partici-
pants were given fluticasone furoate/vilanterol also noted
significantly fewer moderate or severe exacerbations com-
pared with vilanterol alone (rate ratio 0.7; 95 % CI 0.6, 0.8;
p < 0.0001) [79]. In patients with severe airflow limitation(GOLD stage III or IV) and ≥1 exacerbation in the previ-
ous year1, a combination of budesonide/formoterol signifi-
cantly reduced the risk of exacerbations by 28.5, 22.7 and
29.5 % vs placebo, budesonide and formoterol respectively
(p < 0.05 for all) [80]. In a similar population1, budesonide/
formoterol has been reported to reduce severe exacerba-
tions by 24 % vs placebo [81].
The use of ICS in COPD is still controversial [82].
Long-term use of ICS in patients with COPD is associ-
ated with an increased risk of pneumonia [83], fractures
[84] and diabetes [85], among other potential side effects.
With questions concerning the long-term safety of ICS and
also data showing similar exacerbation rates with ICS/
LABA compared with some long-acting bronchodilators
[61], there is emerging consensus that withdrawal of corti-
costeroids may be appropriate in some patient populations.
The WISDOM trial, a 12-month, double-blind, active-
controlled study of 2485 patients with severe/very severe
COPD and a history of exacerbations, showed no increase
in the risk of moderate or severe exacerbations in patients
who withdrew from ICS therapy but remained on LABA/
LAMA compared with those who remained on ICS with
LABA/LAMA [86], although there was an initial drop in
FEV1 of approximately 40 mL. Corticosteroid withdrawal
without long-acting bronchodilation in severe COPD pa-
tients may produce a different pattern of results. This ob-
servation supports a systematic review of other trials of
ICS withdrawal in which there was no conclusive evidence
that withdrawal of ICS increased exacerbations [87]. More-
over, switching to LABA from LABA/ICS has been shown
to occur without loss of efficacy or increase in exacerba-
tions in patients with a low risk of exacerbations in the IN-
STEAD (Indacaterol: Switching Non-exacerbating Patients
with Moderate COPD From Salmeterol/Fluticasone to
Indacaterol) and OPTIMO (Real-Life study On the aPpro-
priaTeness of treatment In MOderate COPD patients)
studies [88, 89].
Patients with ACOS may be particularly likely to bene-
fit from ICS therapy because of the predominance of eo-
sinophilic bronchial inflammation associated with this
COPD phenotype [90–92]. In fact, it has been demon-
strated that a high Th2 signature in COPD correlates
with increased airway wall and blood eosinophil counts,
and greater response of hyperinflation to ICS in COPD
patients with Th2 type of inflammation [92].
The response to ICS in patients with respiratory disease
can be predicted by sputum eosinophil counts [93, 94]. A
randomized crossover trial in patients with COPD in the
absence of clinical diagnosis of asthma demonstrated an
improvement in post-bronchodilator FEV1 with ICS treat-
ment (mometasone furoate) compared with placebo in
those patients with the greatest degree of sputum eosino-
philia [93]. More recently, two post-hoc analyses have
shown that blood eosinophil counts may predict the effects
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rates [95, 96]. Thus, the identification of patients with eo-
sinophilic inflammation in COPD, even in the absence of
asthma, may be a useful phenotype to target those most
likely to benefit from ICS therapy, although this approach
should be validated in prospective studies first.
There is little doubt from the studies reviewed that an
ICS combined with a LABA is an effective intervention
for patients with a history of exacerbations. As shown,
such treatment is associated with reductions in exacer-
bations averaging 25 % compared with placebo and be-
tween 23–36 % (12 % if we include the TORCH study)
compared with LABA monotherapy (Table 3). However,
there is growing evidence indicating that not all patients
with COPD respond to ICS treatment. Given the poten-
tial for pneumonia and other important side effects with
ICS in COPD populations, emerging data reveal that it
may be possible to withdraw the ICS component in cer-
tain patient groups provided that adequate bronchodila-
tion is in place [86–89].
Phosphodiesterase-4 inhibitors
PDE-4 inhibitors represent an anti-inflammatory approach
that is recognized as a treatment option for patients with
COPD who are at high risk of exacerbations and have a
chronic bronchitis phenotype [9]. In a pooled analysis of
two 1-year, placebo-controlled, double-blind, multicenter
studies, roflumilast (a PDE-4 inhibitor) was associated with
a 17 % reduction in the rate of moderate-to-severe exacer-
bations compared with placebo in patients with severe
COPD, chronic bronchitis and a history of previous exacer-
bation (p < 0.0003) (Table 4) [97]. A subsequent systematic
review of 29 trials with PDE-4 inhibitors (15 roflumilast
studies, 14 cilomilast studies) has confirmed these observa-
tions [98]. More recently, roflumilast was noted to reduce
the rate of moderate or severe exacerbations by 13.2 % vs
placebo in high-risk patients (severe COPD, symptoms of
chronic bronchitis and ≥2 exacerbations in the previous
year) receiving LABA/ICS (of which ~70 % were on triple
therapy) in the REACT (Roflumilast and Exacerbations in
patients receiving Appropriate Combination Therapy)
study [99]. Overall, roflumilast is well tolerated with a
safety profile consistent with that expected for the PDE-4
inhibitor class [100]. The most common adverse events
with roflumilast are gastrointestinal in nature, specifically
diarrhea, nausea and weight loss [101]. Psychiatric events
(insomnia, anxiety, depression/suicidal behavior) are also
more common with roflumilast in clinical trials [102].
However, studies have demonstrated beneficial effects of
roflumilast in terms of glycemic parameters [103] and risk
of major adverse cardiovascular events [104].
Overall, current clinical trial data indicate that the PDE-
4 inhibitor roflumilast is associated with a reduction in
the rate of moderate/severe exacerbations of 13–17 %when compared with placebo in a subset of patients that
exhibit symptoms of chronic bronchitis and are at a high
risk of exacerbations despite optimal inhaled therapy.
However, tolerance of roflumilast may be a hurdle for
more extensive use in severe COPD.
Macrolide antibiotics
Bacterial infections can trigger COPD exacerbations and,
consequently, long-term antibiotic use has been consid-
ered as a strategy for the prevention of exacerbations. A
meta-analysis of six randomized controlled trials on the
use of prophylactic macrolide antibiotics has reported a
37 % risk reduction for exacerbations compared with pla-
cebo [105]. A systematic review of seven trials covering
more than 3000 patients identified a significant effect of
continuous antibiotics for reducing the number of patients
experiencing an exacerbation (OR 0.55; 95 % CI 0.30, 0.77)
[106]. Since these analyses, a small study (n = 92) con-
firmed a 42 % decrease in exacerbation rate with mainten-
ance azithromycin treatment compared with placebo (OR
0.58; 95 % CI 0.42, 0.79; p = 0.001) in patients that suffered
at least three exacerbations the previous year while on
maximal respiratory medications (Table 4) [107]. The con-
tinuous use of antibiotics may raise a concern about bac-
terial resistance, and an increase in respiratory pathogens
resistant to macrolides has been identified with this ap-
proach in patients with COPD [108]. Long-term use of
macrolides has also been linked to hearing loss and gastro-
intestinal events [106]. Thus, this approach may be best
for patients who experience frequent bacterial exacerba-
tions despite optimal treatment with bronchodilators and
anti-inflammatory agents [109] and it may be prudent to
limit their use to reference centers with adequate follow-
up [59]. A post-hoc analysis of patients treated with con-
tinuous azithromycin reported that ex-smokers and pa-
tients who are older and have milder COPD may have a
better treatment response [110].
Based on the evidence reviewed here, macrolide anti-
biotic therapy may be a beneficial strategy for patients
who suffer frequent bacterial exacerbations while on max-
imal bronchodilator therapy, as demonstrated in clinical
trials that show reductions in exacerbations ranging from
27 to 42 % compared with placebo (Table 4). Nevertheless,
given the potential for development of bacterial resistance
alongside long-term safety concerns, such treatment needs
to be targeted to the most appropriate patient and include
careful supervision [111].
Mucolytics
Mucolytic therapies, such as carbocysteine or N-
acetylcysteine, may represent an attractive treatment
strategy for frequent exacerbators with chronic bronchitis,
and particularly those who may be unable to receive ICS
(Table 4). A systematic review of 30 trials has reported an
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lytic therapy compared with patients without mucolytic
therapy (OR 1.84; 95 % CI 1.63, 2.07) [112]. However, it
should be noted that there are considerable differences in
the patient populations and definitions of exacerbations
used in these studies; for example, some of these studies
were performed in patients with chronic bronchitis, with-
out the requirement for COPD to be diagnosed. More re-
cently, a study in 1006 patients with moderate-to-severe
COPD in China reported that long-term use of high-dose
N-acetylcysteine (600 mg b.i.d.) was associated with a sig-
nificant decrease in exacerbations compared with placebo
(risk ratio 0.78; 95 % CI 0.67, 0.90; p = 0.0011) [113]. A
smaller study in China has also confirmed a benefit of
high-dose N-acetylcysteine (600 mg b.i.d.) for reducing ex-
acerbations in high-risk patients [114]. Treatment with
mucolytics appears to be well tolerated, with similar fre-
quencies of adverse events compared with placebo [112,
113]. Erdosteine, a mucolytic agent with anti-inflammatory,
antioxidant and bacterial anti-adhesive properties, has re-
cently been reported to reduce the rate (17 %) and duration
(44 %) of exacerbations compared with placebo in patients
with COPD GOLD stage II-III and at least two exac-
erbations requiring medical intervention in the previ-
ous year [115].
In summary, while data indicate that the risk of exacerba-
tion is reduced with mucolytic therapies compared with
placebo in patients with COPD, as demonstrated in
an updated systematic review, much heterogeneity ex-
ists meaning that current data should be interpreted
cautiously [112].
Future therapeutic strategies
A multiple treatment comparison meta-analysis of 26
studies has compared the effects of various combinations
of treatments and noted that, although combination therap-
ies differ in their effects for reducing the risk of COPD ex-
acerbations, they reduce risks more than monotherapy
[116]. Further studies are required to confirm the optimal
combinations for reducing exacerbations. However, ran-
domized controlled studies to evaluate the effects of treat-
ments on exacerbation risk are ongoing or have recently
completed, such as the FLAME study comparing IND/GLY
with SFC [74], and a comparison of umeclidinium/vilan-
terol/fluticasone furoate with fixed-dose dual combinations
of fluticasone furoate/vilanterol and umeclidinium/vilan-
terol [NCT02164513] [117]. Various other combination
therapies are being developed for the prevention of exacer-
bations, including triple therapies of ICS/LABA/LAMA
[11]. In addition, combined PDE-3 and PDE-4 inhibitors
(RPL554), monoclonal antibodies and p38 mitogen acti-
vated protein kinase inhibitors are in development for the
prevention of exacerbations [11]. Benralizumab, an anti-
interleukin-5 (IL-5) receptor alpha monoclonal antibody,has been investigated in Phase II studies in patients with
sputum eosinophilia and COPD [118]. Although no signifi-
cant benefit was noted with benralizumab on the rate of ex-
acerbations in the overall study population, a non-
significant numerical improvement was seen in subgroups
of patients with elevated blood eosinophils [118]. Further
studies with anti-IL-5 therapies are warranted.
Conclusions
There are different risk factors and triggers for COPD ex-
acerbations, and it is increasingly recognized that there
are different phenotypes of patients who are at risk of ex-
acerbations and who may vary in their response to treat-
ments. Various approaches are available for reducing the
risk of exacerbation, and identification of patient pheno-
types may help treatments to be individualized to those
who are most likely to benefit.
Based on the available evidence reviewed herein, we
believe that there is a strong case for maximizing bron-
chodilation as an initial strategy to reduce exacerbation
risk in patients with COPD. For those who persist with
exacerbations despite maximal bronchodilation, we ad-
vocate treatment according to their phenotype (Fig. 1)
[119–121]. While current global guidelines recommend
ICS treatment in symptomatic patients at high risk of an
exacerbation (GOLD D), it should be borne in mind that
this is based on a limited number of studies. Further,
attempting to enhance the effect of ICS with additional
theophylline does not reduce exacerbation rates [120]. Our
evolving understanding in this area suggests that a more
careful targeting of ICS may optimize the benefit-to-risk
ratio. There is some evidence that ICS treatment is most
effective in patients with higher eosinophil counts [95, 96],
although these data are primarily from retrospective ana-
lyses and require further validation by prospective data.
However, the recent FLAME study, which prospectively
examined treatment effects according to baseline blood
eosinophil count, found that the rate of exacerbations was
significantly lower with IND/GLY compared with SFC irre-
spective of eosinophil count (i.e. <2 % or ≥2 %) [74].
Whether the outcome in FLAME was due to the fact that
this was a comparison of a LABA/LAMA versus SFC,
compared with other studies which have looked at a LABA
compared with SFC, remains to be determined. Post hoc
analysis of WISDOM suggests that withdrawal of ICS in
the subgroup of patients with higher eosinophils may in-
crease risk of exacerbation, but this also remains to be pro-
spectively studied [121]. In exacerbators with chronic
bronchitis we propose treatment with ICS (as per the
Spanish GesEPOC guidelines [33]) or roflumilast, and in
selected patient groups in whom ICS cannot be used,
high-dose mucolytics. In exacerbators with chronic bron-
chitis who produce dark sputum and have previously re-
quired multiple courses of antibiotics, caution is advised
Fig. 1 Therapeutic recommendations based on exacerbation phenotype. ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist
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ial complications. A pragmatic approach may therefore be
to use macrolides in reference centers with close clinical
and microbiological follow-up. Finally, in exacerbators with
emphysema we should emphasize the importance of max-
imal bronchodilation and consider adding ICS in patients
with higher blood eosinophil counts. Additionally, non-
pharmacologic therapy including pulmonary rehabilitation
should be included as part of a comprehensive management
plan for all patients at risk of exacerbation episodes due to
benefits in terms of reductions in risk of hospitalizations.Endnotes
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2Included in the network meta-analysis.Additional file
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